Item 7.01 Regulation FD Disclosure.
On
The Presentation will highlight the latest innovations and treatment pathways in immunology, including an overview of the Company's novel DiversitAb™ platform, and data from completed clinical trials that indicate the Company's polyclonal antibody therapies can provide long-lasting efficacy against numerous highly mutating pathogens or multiple targets or pathways at once. A copy of the Presentation is furnished herewith as Exhibit 99.2 and is incorporated herein by reference. Additionally, the Company will make an audio recording of the Presentation available on the Company's investor relations website prior to the Biotech Showcase Presentation at https://ir.sab.bio/.
The foregoing (including Exhibits 99.1 and 99.2) are being furnished pursuant to
Item 7.01 of Form 8-K and will not be deemed to be filed for purposes of Section
18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"),
or otherwise be subject to the liabilities of that section, nor will it be
deemed to be incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act. The information contained in each of the
press release and the Presentation is summary information that should be
considered in the context of the Company's filings with the
Cautionary Note Regarding Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking
statements for purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Forward-looking statements generally
are accompanied by words such as "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect," "should," "would," "plan,"
"predict," "potential," "seem," "seek," "future," "outlook" and similar
expressions that predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements include, but
are not limited to, statements regarding future events, including the
development and efficacy of our influenza program, C. diff. program, Type 1
Diabetes program, and other discovery programs, the likelihood that a patent
will issue from any patent application, the results, including timing, of the
development of
These statements are based on the current expectations of
Item 9.01 Financial Statements and Exhibits.
Exhibit Number Description 99.1 Press Release of the Company, datedJanuary 9, 2023 99.2 Presentation datedJanuary 10, 2023 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
--------------------------------------------------------------------------------
© Edgar Online, source